Anthony Cuomo
Pulmonary Disease · San Diego, CANPI 1356440465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,146 and has fallen 86.2% since, to $158 in 2023.
Across 227 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$600
- AstraZeneca$589
- Boehringer Ingelheim$513
- Regeneron Healthcare Solutions, Inc.$242
- Philips North America LLC$226
- Actelion Pharmaceuticals US, Inc.$195
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,080100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $600 |
| AstraZeneca | 34 | $589 |
| Boehringer Ingelheim | 26 | $513 |
| Regeneron Healthcare Solutions, Inc. | 9 | $242 |
| Philips North America LLC | 23 | $226 |
| Actelion Pharmaceuticals US, Inc. | 12 | $195 |
| Sanofi | 10 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $173 |
| Insmed, Inc. | 7 | $158 |
| Mylan Specialty L.p. | 5 | $112 |
| Grifols USA, LLC | 5 | $97 |
| Pfizer | 5 | $81 |
| Gilead | 3 | $72 |
| Merck | 4 | $71 |
| Sunovion Pharmaceuticals Inc. | 9 | $62 |
| Baxter Healthcare | 2 | $60 |
| Genentech USA, Inc. | 3 | $57 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| Johnson & Johnson | 3 | $51 |
| Advanced Respiratory, Inc | 2 | $50 |
| Sanofi Pasteur Inc. | 3 | $46 |
| Amgen | 2 | $45 |
| Hospira, Inc. | 2 | $44 |
| Circassia Inc. | 3 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Resmed Corp | 2 | $36 |
| Electromed, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Harmony Biosciences LLC | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Pulmonx Corporation | 2 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Pentax Of America, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$4,096 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in San Diego
- George ChengSan Diego$291K
- Samir MakaniSan Diego$179K
- Shari BrazinskySan Diego$82K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.